In lipid nanoparticle (LNP) development, co-delivery means transporting two or more functional payloads within a coordinated formulation so that they reach the intended tissue, cell population, and intracellular compartment in a useful ratio and time window. The payloads may be two nucleic acids, an RNA and a small molecule, an antigen and an immunostimulant, or several components required for genome editing. True co-delivery therefore involves more than placing two materials in the same vial. It requires control over loading, particle association, biodistribution, cellular uptake, release, and functional interaction.
A lipid nanoparticle co-delivery project can use a single particle population containing both cargos, a defined mixture of payload-specific LNPs, or a staged system designed to release one component before another. The best architecture depends on whether the payloads must act in the same cell, whether a fixed molar ratio is important, and whether their physicochemical properties are compatible with one formulation process. These distinctions should be established before lipid screening begins because they determine the analytical plan and the meaning of a successful formulation.
Many biological processes cannot be controlled effectively through one molecular action. A gene-editing system may require an editor-encoding mRNA and a guide RNA in the same cytoplasm. A combination gene therapy may need one RNA to restore a missing protein and another to suppress a harmful pathway. A vaccine may benefit when antigen expression and innate immune stimulation occur in the same antigen-presenting cell. In these situations, separate administration can produce unequal tissue exposure, different uptake probabilities, or a time gap that weakens the intended interaction.
Multi-payload LNPs can improve spatial coordination by increasing the probability that interacting cargos reach the same cell. They can also protect fragile nucleic acids from extracellular degradation, align their pharmacokinetic behavior, and reduce variability caused by administering several independent formulations. For LNP-mediated gene delivery, this coordination is especially important when functional activity depends on the intracellular assembly of multiple components rather than the independent activity of each cargo.
Co-delivery is not automatically superior. Combining payloads can lower the loading efficiency of one component, destabilize the particle, or force both cargos to follow the same release profile even when their optimal release times differ. The development objective is therefore not maximum loading of every component. It is a reproducible formulation that delivers a biologically effective ratio while maintaining the integrity and activity of each payload.
Clinical-stage genome-editing candidates provide clear examples of why coordinated LNP delivery matters. The candidates below use an LNP to transport an editor-encoding mRNA together with a target-specific guide RNA. Both components must reach the same hepatocyte and become available in the correct sequence: the mRNA is translated into an editing protein, the guide RNA associates with that protein, and the resulting complex acts at the selected genomic site. Development stages described here reflect publicly available information as of July 2026 and should be updated as programs advance.
NTLA-2001 is an investigational liver-directed LNP containing an mRNA that encodes Cas9 and an sgRNA targeting the transthyretin gene, TTR. The design illustrates same-particle delivery of a large mRNA and a much shorter guide RNA with substantially different molecular sizes and structural properties. Its development has progressed into Phase 3 studies. From a formulation perspective, NTLA-2001 demonstrates the need to protect both RNA species, preserve their functional ratio, and achieve productive cytoplasmic release in hepatocytes.
NTLA-2002 uses an LNP to deliver Cas9 mRNA and an sgRNA directed toward KLKB1, which encodes plasma kallikrein. The candidate has reached Phase 3 development. Although its cargo format resembles that of NTLA-2001, the guide sequence, target biology, effective exposure, and required editing profile differ. This comparison shows why an LNP composition cannot be assumed to perform identically after only changing the guide RNA: RNA sequence, folding, purity, and association with ionizable lipids can influence encapsulation and intracellular availability.
VERVE-102 is an investigational GalNAc-LNP carrying an mRNA that encodes an adenine base editor and a guide RNA targeting PCSK9. It has been evaluated in Phase 1b development, with further clinical evaluation planned. Compared with conventional Cas9 nuclease delivery, base-editor mRNA can impose a different size, translation, and exposure requirement. The surface targeting element adds another design variable because ligand density, PEG presentation, particle uptake, and endosomal escape must be balanced without disrupting the co-loaded RNA ratio.
YOLT-101 is an investigational GalNAc-modified LNP that co-encapsulates adenine base editor mRNA and an sgRNA targeting PCSK9. Phase 1 findings have been reported. The surface GalNAc modification promotes hepatocyte-directed uptake, while the ionizable LNP structure supports the coordinated encapsulation, protection, and cytoplasmic release of both RNA components.
These examples are investigational rather than marketed gene-editing LNP products. Their relevance to formulation research lies in the shared engineering problem: heterogeneous RNA cargos must be packaged, retained, delivered, and released together while each remains functional.
Both payloads are introduced during one particle-formation process and are intended to occupy the same LNP population. This architecture offers the strongest potential for same-cell exposure and is preferred when activity requires intracellular assembly, as with editor mRNA and guide RNA. However, bulk encapsulation efficiency does not prove that every particle contains both components. Co-encapsulation of multiple payloads in LNPs should therefore be supported by cargo-specific assays and, where feasible, particle-level distribution analysis.
Each cargo is formulated separately under conditions optimized for its own properties, and the resulting LNP populations are mixed at a defined dose ratio. This approach reduces direct cargo competition during assembly and can simplify independent optimization. Its main limitation is probabilistic co-uptake: two LNP populations may distribute differently or enter different cells. It is suitable when the cargos can act in neighboring cells, when exact same-particle loading is unnecessary, or when a single formulation causes unacceptable instability.
A hydrophobic drug, adjuvant, or functional molecule can be chemically linked to a lipid-compatible anchor or incorporated as a prodrug-like lipid component. The modified cargo partitions into the LNP lipid domain while a nucleic acid remains associated with the ionizable lipid-rich interior. This arrangement can improve retention and reduce competition between hydrophilic and hydrophobic cargos. It also introduces new questions concerning linker stability, conversion to the active molecule, and whether the modified cargo changes membrane packing. These considerations are central to small-molecule delivery with LNPs.
Some combinations require a defined order of action. One payload may first sensitize a pathway, remodel a cellular state, or create the molecular substrate required by the second payload. Sequential systems may use separate LNPs administered at different times, compartments with different release rates, or responsive lipids and linkers activated by pH, enzymes, redox conditions, or other local signals. A meaningful nanoparticle drug release program must measure both cargos independently rather than report one overall release curve.
Table 1. Decision Framework for Selecting an LNP Co-Delivery Architecture.
| Architecture | Best-Fit Requirement | Main Advantage | Primary Development Risk |
| Single-LNP co-encapsulation | Both cargos must act in the same cell | Highest potential for coordinated intracellular exposure | Competitive loading and particle-to-particle cargo heterogeneity |
| Mixed LNP populations | Each cargo needs a different formulation | Independent optimization and flexible dose ratio | Divergent biodistribution or incomplete cellular co-uptake |
| Lipid-integrated cargo | Hydrophobic companion cargo requires strong retention | Improved lipid-domain compatibility | Altered particle structure or incomplete active-cargo release |
| Sequential or responsive delivery | Biological activity depends on order or timing | Programmable temporal control | Complex release measurement and batch reproducibility |
BOC Sciences develops an appropriate co-delivery strategy based on your payload types, physicochemical properties, required cargo ratio, target cells, and release sequence.
Co-formulated payloads rarely associate with lipids at identical rates. A long mRNA has many anionic sites and a large hydrodynamic volume, whereas a short guide RNA or siRNA has fewer binding sites and different folding behavior. During rapid mixing, the larger cargo may dominate ionizable-lipid association, leaving the smaller cargo under-encapsulated or concentrated in a different particle subpopulation. Feed ratio alone therefore does not define the final encapsulated ratio. Development should measure total recovery, free cargo, encapsulated content, and the molar ratio after purification. LNP encapsulation efficiency optimization can then adjust the N/P ratio, total cargo concentration, flow-rate ratio, and RNA addition sequence around the weaker-loading component.
One payload can alter the solubility, conformation, or chemical environment of another. Hydrophobic drugs may disrupt lipid packing; peptides and proteins may adsorb to RNA or the particle surface; and mixed nucleic acids may form aggregates before lipid association. These interactions can increase particle size, broaden PDI, reduce recovery, or cause leakage during buffer exchange and storage. A useful stress program separates physical instability from cargo degradation by monitoring size, PDI, zeta potential, turbidity, cargo integrity, and payload retention at defined time points.
Efficient co-encapsulation can still produce poor functional activity when the payloads are released at incompatible rates. Strong electrostatic binding may protect RNA but delay cytoplasmic availability. A hydrophobic small molecule may remain in the lipid phase after the nucleic acid has escaped, whereas a surface-associated adjuvant may separate too early. Formulation teams should define the required biological sequence first and then build cargo-specific release methods. Nanoparticle drug release profiling under extracellular, endosomal-like, and cytosolic-mimicking conditions can reveal whether release order matches the proposed mechanism.
A single total-nucleic-acid result cannot distinguish two RNA species, and high average encapsulation may hide a population of single-loaded or empty particles. Each cargo requires a selective measurement with demonstrated specificity in the presence of the second payload and the lipid matrix. Orthogonal methods may include sequence-selective amplification, electrophoretic separation, chromatographic analysis, mass-based assays, imaging, or single-particle measurements. Analytical planning should also cover free-payload separation, recovery controls, dilution linearity, and interference testing. Combining LNP encapsulation efficiency testing with nanoparticle structural characterization provides a stronger view of both composition and architecture.
This section translates the preceding failure modes into practical formulation decisions. A robust strategy begins with a target product profile for the research formulation: cargo identities, required intracellular ratio, preferred architecture, target cell, release order, acceptable particle window, and functional readouts. Lipid nanoparticle formulation should then proceed through staged screening rather than changing several composition and process variables at once.
Lipid composition determines how cargos associate during mixing, how the particle remains intact after purification, and how the payloads become available after cellular uptake. Ionizable-lipid structure and apparent pKa affect RNA complexation and endosomal membrane interaction. Helper lipids influence membrane order and fusion, cholesterol controls packing and stability, and PEG-lipids regulate particle size, aggregation, and surface accessibility. For multi-cargo systems, the best composition is the one that balances the weakest payload without unnecessarily suppressing the activity of the stronger one.
Table 2. Lipid Composition Variables for Multi-Cargo Compatibility.
| Composition Variable | Role in Co-Delivery | Variables to Screen | Decision Readouts |
| Ionizable Lipid | Complexes nucleic acids and supports endosomal release | Headgroup chemistry, linker, tail structure, apparent pKa, N/P ratio | Cargo-specific EE%, RNA integrity, endosomal escape, expression or editing |
| Helper Lipid | Controls membrane order, fusogenicity, and cargo release | Saturated versus unsaturated chains, headgroup type, molar fraction | PDI, leakage, membrane interaction, functional delivery |
| Cholesterol Content | Fills packing defects and supports structural stability | Cholesterol level, sterol analogue, lipid-domain compatibility | Particle morphology, retention, storage stability, release rate |
| Total Lipid Ratio | Balances loading capacity, stability, and intracellular performance | Ionizable/helper/sterol/PEG-lipid molar ratios | Dual-cargo ratio, recovery, size, potency, batch consistency |
| PEG-Lipid | Controls size and aggregation while affecting uptake and ligand access | Anchor length, PEG chain length, mol%, shedding behavior | Colloidal stability, uptake, ligand presentation, endosomal delivery |
Composition screening should use a matrix that records both individual-cargo and combined-function outcomes. Ranking formulations only by particle size or total encapsulation can select a stable but biologically inactive candidate. A weighted score may instead combine cargo ratio, integrity, release, cell delivery, and the intended functional endpoint.
Loading order can determine which cargo occupies the ionizable-lipid-rich domains and which remains near the particle surface. Simultaneous mixing is efficient when cargos have similar solvent tolerance and lipid-association kinetics. Sequential loading is more useful when one component must establish the particle core before the second is introduced, or when a sensitive protein, peptide, or drug cannot tolerate the initial low-pH or solvent conditions. Post-insertion can add a lipid-anchored cargo or targeting element after particle formation, while separate formulation followed by blending avoids direct competition entirely.
Table 3. Cargo Loading Sequence Strategies for LNP Co-Formulation.
| Loading Strategy | Best-Fit Cargo Pair | Main Benefit | Key Risk and Verification |
| Simultaneous Co-Mixing | Two RNAs with compatible buffers and processing tolerance | One-step formation and high same-particle potential | Competitive loading; verify each cargo after purification |
| Sequential Encapsulation | RNA plus protein, peptide, or differently charged nucleic acid | Greater control over cargo association order | Particle restructuring; monitor size, leakage, and activity after each step |
| Post-Insertion or Remote Loading | Lipid-anchored ligand, hydrophobic drug, or membrane-partitioning cargo | Avoids exposing the second cargo to initial mixing conditions | Surface heterogeneity or incomplete insertion; quantify free and associated cargo |
| Separate LNP Preparation and Blending | Payloads requiring incompatible compositions or release profiles | Independent optimization and adjustable dose ratio | Incomplete same-cell uptake; assess dual-positive cells and tissue distribution |
| Purification-Integrated Loading | Systems sensitive to free payload or exchange conditions | Links loading development with removal of unencapsulated material | Selective cargo loss; apply free-payload removal recovery controls |
The preferred sequence should be selected using mass balance. Measure each cargo before formulation, after particle formation, after purification, and after any concentration or buffer-exchange step. This identifies the operation responsible for ratio drift and prevents repeated reformulation when the actual loss occurs downstream.
Microfluidic mixing creates LNPs through rapid solvent exchange and lipid-cargo association. In a co-delivery system, small changes in total flow rate, flow-rate ratio, channel geometry, temperature, or input concentration may affect the two payloads differently. Process optimization should therefore track cargo-specific responses rather than assume that parameters established for one RNA will transfer to a dual-payload formulation. A structured microfluidic LNP production study can identify a robust operating region instead of a single favorable setting.
Table 4. Microfluidic Parameters Governing LNP Co-Formulation.
| Process Parameter | Effect on Co-Delivery LNPs | Optimization Goal | Typical Failure Signal |
| Total Flow Rate | Changes mixing time, nucleation, particle size, and cargo capture | Narrow size distribution with stable dual-cargo recovery | Size shift or cargo-ratio change across flow conditions |
| Flow-Rate Ratio | Controls solvent dilution and local lipid-to-cargo exposure | Rapid assembly without precipitation or weak encapsulation | Low recovery of the shorter or less strongly associating cargo |
| Input Concentration | Affects collision frequency, loading capacity, and aggregation | Useful payload concentration without excessive PDI | Turbidity, large particles, or nonlinear encapsulation |
| Mixing Geometry | Determines micromixing pattern and scale sensitivity | Select geometry matched to viscosity and throughput | Different cargo ratio after transfer between devices |
| Hydrodynamic Flow Focusing | Provides controlled central-stream focusing | Reproducible solvent exchange for low-to-moderate viscosity feeds | Channel-position sensitivity or broad size distribution |
| Staggered Herringbone Mixing | Enhances chaotic advection and rapid mixing | Efficient assembly across a practical throughput range | Overmixing-sensitive cargo damage or device-specific transfer effects |
| Dean Flow Mixing | Uses secondary flow for rapid radial transport | Higher-throughput mixing with controlled particle formation | Scale-dependent residence time or cargo recovery |
After identifying a lead composition, process robustness should be tested around the selected settings. Deliberate small changes reveal whether size, PDI, cargo ratio, and functional activity remain stable. This work also supports rational LNP process scale-up by distinguishing geometry-dependent variables from transferable mixing principles.
Targeting is valuable only when it improves productive delivery of both payloads. Adding a ligand can change particle size, surface charge, protein adsorption, uptake pathway, and endosomal trafficking. The ligand may also compete with PEG shielding or destabilize a formulation that was optimized before conjugation. Surface engineering should therefore be integrated early enough to allow composition adjustment, but after a workable cargo-loading system has been established. Nanoparticle surface functionalization studies should optimize ligand identity, spacer, orientation, density, and attachment method together with dual-cargo activity.
Table 5. Surface Modification Options for Targeted LNP Co-Delivery.
| Surface Strategy | Potential Co-Delivery Purpose | Critical Design Variable | Verification Readout |
| GalNAc-Conjugated LNPs | Promote hepatocyte-directed delivery of multi-component RNA systems | Ligand valency, spacer length, density, and PEG competition | Receptor-dependent uptake, hepatocyte delivery, dual-cargo function |
| Aptamer-Conjugated LNPs | Direct payload combinations toward selected cell-surface markers | Aptamer folding, attachment position, nuclease stability | Binding selectivity, uptake competition, cargo activity |
| Peptide-Functionalized LNPs | Support cell binding, tissue penetration, or intracellular trafficking | Peptide orientation, charge, density, and proteolytic stability | Particle stability, cell uptake, penetration, endosomal release |
| Antibody-Conjugated LNPs | Increase cell-type selectivity for potent multi-cargo systems | Conjugation site, antibody format, ligand-to-particle ratio | Binding retention, uptake selectivity, dual-positive cell fraction |
| Stimulus-Responsive Surface | Expose a ligand or alter charge only in the target microenvironment | Trigger threshold, cleavage rate, and premature activation | Condition-dependent surface change and cargo delivery |
Targeting evaluation should distinguish particle binding from functional cytoplasmic delivery. An increase in total cell-associated fluorescence may reflect surface adhesion or endosomal trapping. Cargo-specific expression, silencing, editing, or pathway modulation provides a more meaningful endpoint, particularly when both components must act in the same cell.
BOC Sciences can compare cargo-specific encapsulation, recovery, retention, and functional activity to identify whether the limiting factor is cargo chemistry, lipid composition, or process design.
Co-delivering an antigen-encoding mRNA with an immunostimulatory component can coordinate antigen production and innate activation within the same antigen-presenting cell. The formulation must preserve mRNA translation while controlling the strength, location, and duration of stimulation. Excessive adjuvant exposure may reduce translation or alter cell viability, whereas weak or prematurely separated stimulation may fail to support antigen presentation. For this application, LNP vaccine development should evaluate antigen expression, dendritic-cell uptake, cytokine profile, and antigen-specific immune readouts as connected variables rather than independent endpoints.
Multi-gene strategies can combine protein restoration with gene silencing, deliver several mRNAs for a multi-subunit protein, or transport the RNA components required for nuclease, base-editing, or prime-editing systems. Cargo length and required stoichiometry may differ widely. The formulation must also account for translation timing and the persistence of each component. Lipid nanoparticles for mRNA delivery can be combined with guide RNA, siRNA, ASO, or other nucleic acid formats when same-cell activity is demonstrated rather than assumed.
A gene-silencing payload may reduce a resistance pathway while a small-molecule drug acts on cell survival or proliferation. This combination is attractive because the two cargos can address different mechanisms, but the formulation challenge is substantial: siRNA is hydrophilic and polyanionic, whereas many small molecules partition into hydrophobic lipid domains. LNP-based siRNA delivery must retain silencing activity while drug loading, leakage, and release remain independently measurable. Tumor-targeted LNP development may further improve spatial coordination when the selected ligand and particle properties support productive delivery to the intended tumor cell population.
Co-delivery platforms can combine antigen-encoding RNA or protein with an immunostimulant, multiple antigen sequences, or components intended to broaden the immune response. The required cargo ratio may differ by antigen and target immune population. Lipid nanoparticles for antigen delivery should be evaluated for antigen integrity or expression, particle uptake by relevant immune cells, innate signaling, and downstream functional responses. The same formulation should not be assumed optimal for every antigen-adjuvant pair because payload sequence, molecular size, and immune activity can change the usable design window.
BOC Sciences supports architecture selection, cargo-specific analytical development, formulation screening, release design, targeting, and functional evaluation for multi-payload LNP research.
Support begins with a structured review of payload chemistry, molecular size, charge, solvent and pH tolerance, target cell, intracellular destination, and required sequence of action. BOC Sciences compares single-particle co-encapsulation, mixed LNP populations, lipid-integrated cargo, and sequential delivery before experimental screening. Early feasibility work identifies likely cargo-cargo interactions and establishes cargo-specific methods for recovery and integrity. This prevents a formulation from appearing successful only because one component dominates the bulk analytical result.
BOC Sciences develops multi-cargo formulations through lipid screening, N/P and lipid-to-cargo ratio optimization, buffer selection, loading-sequence studies, and microfluidic parameter evaluation. LNP process optimization links composition variables with total flow rate, flow-rate ratio, concentration, mixing geometry, purification, and buffer exchange. When low recovery, aggregation, or ratio drift persists, LNP encapsulation troubleshooting isolates the process step responsible for the failure.
The team establishes an effective rather than merely convenient cargo ratio and studies how that ratio changes after formulation, purification, storage, cell uptake, and release. Responsive lipid or linker designs can be evaluated when the two cargos require different release windows. For tissue- or cell-selective delivery, targeted LNP development can integrate passive particle-property tuning with ligand selection and density optimization. The final design is assessed for delivery of both cargos, not only for particle accumulation.
BOC Sciences provides cargo-specific content and integrity measurements alongside particle size, PDI, zeta potential, morphology, structure, stability, and leakage analysis. Nanoparticle analysis and characterization can be combined with nanoparticle in vitro evaluation, cellular uptake testing, and intracellular localization detection. Where required, LNP endosomal escape evaluation and nanoparticle in vivo distribution analysis help connect particle behavior with functional co-delivery.
Table 6. Recommended BOC Sciences Services for LNP Co-Delivery Projects.
| Recommended Service | Project Scope | Key Outputs | Inquiry |
| Multi-Payload LNP Encapsulation Development | Cargo compatibility, architecture comparison, N/P ratio, feed ratio, loading sequence, and purification design | Feasibility assessment, formulation candidates, cargo-specific EE% and recovery | Inquiry |
| Dual-Payload LNP Stability and Retention | Aggregation, leakage, cargo integrity, buffer effects, stress conditions, and storage screening | Stability profile and cargo-specific retention data | Inquiry |
| Dual-Payload Loading and Ratio Analysis | Independent quantification of each cargo, free-payload measurement, mass balance, and ratio tracking | Cargo content, loading efficiency, molar ratio, and recovery report | Inquiry |
| Sequential and Stimulus-Responsive Release Design | Release-order design, trigger selection, cargo-specific release methods, and functional timing studies | Release profiles under selected conditions and recommended responsive design | Inquiry |
| Targeted Co-Delivery LNP Functionalization | Ligand selection, spacer and conjugation design, surface density optimization, and free-ligand removal | Functionalized LNP candidates with ligand-density and binding data | Inquiry |
| LNP Process Development and Scale-Up | Microfluidic process definition, robustness testing, purification integration, and scale translation | Defined process parameters, reproducibility data, and development batches | Inquiry |
Lipid nanoparticle co-delivery has matured from a conceptual advantage into a validated engineering discipline, demonstrated by clinical-stage programs that co-encapsulate editing mRNAs with guide RNAs and by a growing toolkit of architectures, formulation strategies, and analytical methods. The persistent hurdles, encapsulation imbalance, cargo interference, differential release, and dual-payload quantification, are increasingly manageable through deliberate lipid design, controlled loading sequences, microfluidic process discipline, and orthogonal characterization. For research teams pursuing combination therapeutics, the practical path is to select the right architecture early, screen formulation space systematically, and verify both cargos at every stage. BOC Sciences provides the integrated services needed to take a co-delivery concept from a cargo pair to an optimized, characterized LNP ready for biological evaluation.
References
